dacarbazine has been researched along with decitabine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, R; Kaye, SB; Plumb, JA; Sludden, J; Strathdee, G | 1 |
| Gong, F; Ji, SP; Li, AM; Tai, JL; Zhang, YP; Zheng, CQ | 1 |
| Geng, J; Luo, H; Pu, Y; Wu, X; Xu, W; Yang, Z; Zhou, Z | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Jiang, Z; Kuo, PY; Leshchenko, VV; Parekh, S; Thirukonda, VK | 1 |
| Dolan, ME; Godley, LA; Moen, EL; Stark, AL; Zhang, W | 1 |
| Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C | 1 |
| Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH | 1 |
| Berdasco, M; Caba, O; Cabeza, L; Gónzalez, B; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J | 1 |
1 review(s) available for dacarbazine and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for dacarbazine and decitabine
| Article | Year |
|---|---|
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
10 other study(ies) available for dacarbazine and decitabine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Base Pair Mismatch; Carboplatin; Carrier Proteins; Cisplatin; Colonic Neoplasms; Dacarbazine; Decitabine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azacitidine; Brain Neoplasms; Cell Line, Tumor; CpG Islands; Dacarbazine; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Survival Rate; Temozolomide; Young Adult | 2009 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Decitabine; Down-Regulation; Epigenesis, Genetic; Gene Silencing; Glioma; Humans; Methylation; MicroRNAs; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide | 2012 |
Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genomics; Humans; Lymphoma, Large B-Cell, Diffuse; Promoter Regions, Genetic; Temozolomide; Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; CpG Islands; Cytosine; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Quantitative Trait Loci; Temozolomide; Tumor Suppressor Proteins | 2014 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompatible Materials; Boron Compounds; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Lactic Acid; Magnetic Resonance Spectroscopy; Methacrylates; Methylmethacrylates; Micelles; Nanoconjugates; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectrometry, Fluorescence; Temozolomide | 2015 |
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycoproteins; Guanine; Humans; Inhibitory Concentration 50; Peptides; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |